The Director, HTA, Value & Evidence (HV&E) - Migraine (Secondment, 6 months) will support the strategic goals of the Primary Care Division by driving optimal patient access for migraine medicines. This role directly impacts the ability to achieve business objectives on a global basis by providing strategic guidance and robust evidence development relevant to achieve optimal patient access by demonstrating the value of our migraine medicines. The HV&E Director will be responsible for developing and executing against the global evidence generation strategy, including direct oversight of evidence generation activities and dissemination of technical deliverables. This position will be part of Pfizer’s dynamic Global Access & Value (GAV) team and will have the important role of managing health economics and outcomes research (HEOR) to generate data to support patient access to migraine medicines, with a particular focus on economic modelling and indirect treatment comparisons in support of rimegepant. Based on the needs of the migraine franchise, this colleague is expected to work across different geographies. Flexibility is expected given the evolving pricing and access strategy and competitor. This position will be working closely with the migraine GAV, cross-functional and country teams to foster a culture that promotes innovation and thrives on doing better for Pfizer’s patients and healthcare.